Aeterna Zentaris has appointed Boehringer Ingelheim’s Dr Richard Sachse as senior VP and chief scientific officer.
Dr Sachse was most recently head of global translational medicine at Germany-based Boehringer following several roles at major pharma companies in Europe, including Bayer, Schwarz Pharma and UCB.
He will now make the move to Canada to take on his role at Aeterna Zentaris, which specialises in oncology and endocrinology.
The company’s president and CEO David Dodd outline Dr Sachse’s new role: “As CSO, he will be responsible for all areas of our global research and development activities, while also serving on the corporate operating committee.”
Dr Sachse said he was “delighted” by the opportunity his new position offered him.
He said: “I believe that the combination of Aeterna Zentaris’ highly qualified and motivated personnel, together with its strong scientific platform, holds much promise for the future success of our projects.”